Markets:

Overview

News

Currencies

International

Treasuries

Alvotech - Ordinary Shares (NQ:ALVO)

5.185 +0.135 (+2.67%)

Streaming Delayed Price Updated: 2:00 PM EST, Dec 31, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alvotech - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma

December 22, 2025

From Alvotech

Via GlobeNewswire

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

December 19, 2025

According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain...

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

December 16, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Earnings Scheduled For November 12, 2025 ↗

November 12, 2025

Via Benzinga

Bragar Eagel & Squire, P.C. Continues Investigations into Beyond Meat and Alvotech on Behalf of Stockholders and Encourages Investors to Contact the Firm

December 15, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

December 12, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

December 09, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

December 06, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation – ALVO

December 04, 2025

From The Rosen Law Firm, P.A.

Via Business Wire

Alvotech’s Drug Approved In Europe As Biosimilar For Bone Disease Drug ↗

November 24, 2025

AVT03 will be commercialised in Europe in partnerships with STADA Arzneimittel AG and Dr. Reddy’s, the company said.

Via Stocktwits

Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area

November 24, 2025

From Alvotech

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Continues Investigations into Regencell, Beyond Meat, Alvotech, and Camping World on Behalf of Stockholders and Encourages Investors to Contact the Firm

November 22, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)

November 20, 2025

From Alvotech

Via GlobeNewswire

ALVO Investigation: Investors Encouraged to Contact Kirby McInerney LLP

November 19, 2025

From Kirby McInerney LLP

Via Business Wire

Ardent Health, KinderCare Learning, Ibotta And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

November 13, 2025

Via Benzinga

Bragar Eagel & Squire, P.C. Is Investigating Regencell, Beyond Meat, Alvotech, and Camping World and Encourages Investors to Contact the Firm

November 12, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update

November 12, 2025

From Alvotech

Via GlobeNewswire

Uncovering Potential: Alvotech's Earnings Preview ↗

November 11, 2025

Via Benzinga

UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)

November 10, 2025

From Alvotech

Via GlobeNewswire

ALVOTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating Alvotech on Behalf of Alvotech Stockholders and Encourages Investors to Contact the Firm

November 07, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA

November 06, 2025

From Alvotech

Via GlobeNewswire

ALVOTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating Alvotech on Behalf of Alvotech Stockholders and Encourages Investors to Contact the Firm

November 05, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Alvotech INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors (ALVO)

November 04, 2025

From Kirby McInerney LLP

Via GlobeNewswire

Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update

November 04, 2025

From Alvotech

Via GlobeNewswire

This Kimberly-Clark Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

November 04, 2025

Via Benzinga

Top 3 Health Care Stocks Which Could Rescue Your Portfolio In November ↗

November 04, 2025

Via Benzinga

Which stocks are moving on Monday? ↗

November 03, 2025

Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Gold Edges Higher; ISM Manufacturing PMI Falls In October ↗

November 03, 2025

Via Benzinga

Alvotech Shares Plunge 33% After FDA Flags Issues ↗

November 03, 2025

Alvotech shares decline after the FDA issues a complete response letter for its Simponi biosimilar, leading to a lower 2025 revenue and EBITDA outlook.

Via Benzinga

Top movers analysis in the middle of the day on 2025-11-03: top gainers and losers in today's session. ↗

November 03, 2025

Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.